Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.
暂无分享,去创建一个
L. Seymour | M. Moore | W. Stadler | H. von der Maase | L. Dogliotti | D. Roychowdhury | A. Hayden | D. Kaufmann
[1] P. Albers,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Raghavan,et al. Progress in the management of metastatic bladder cancer. , 2000, Cancer control : journal of the Moffitt Cancer Center.
[3] H. Maase. Gemcitabine in locally advanced and/or metastatic bladder cancer , 2000 .
[4] W. Oh,et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. von der Maase,et al. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer , 2000, Cancer Chemotherapy and Pharmacology.
[6] L. Crinò,et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] I. Tannock,et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Bacik,et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Kuzel,et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Mazumdar,et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Neuberg,et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] I. Tannock,et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Logothetis,et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Geller,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.
[16] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .